Adaptation of renal function in heart failure

Renal Failure

Volumn 28, Issue 7, 2006, Pages 527-535

  Makaritsis, Konstantinos P ^a   Liakopoulos, Vassilios ^a   Leivaditis, Konstantinos ^a   Eleftheriadis, Theodoros ^a   Stefanidis, Ioannis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Cardiorenal syndrome; Heart failure; Renal adaptation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; LOSARTAN; NATRIURETIC FACTOR; SPIRONOLACTONE; VASOPRESSIN;

ADAPTATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIURESIS; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; INDUSTRIALIZATION; KIDNEY DISEASE; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SYMPTOMATOLOGY;

ACCLIMATIZATION; ANIMALS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 33750039146     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220600839522     Document Type: Review

References (69)

1. Colucci W, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: Saunders; 1997:394-420.
2. Cohn JN, Bristow MR, Chien KR et al. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation. 1997;95:766-770.
3. American Heart Association. Heart Disease and Stroke Statistics - 2006 Update. Dallas, Tex.: American Heart Association; 2006.
4. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703-712.
5. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A-13A.
6. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951-957.
7. Konstam MA. Progress in heart failure management? Lessons from the real world. Circulation. 2000;102:1076-1078.
8. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
9. MacIntyre K, Capewell S, Stewart S et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126-1131.
10. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
11. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-210.
12. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-1009.
13. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988;319:1065-1072.
14. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988;319:1127-1134.
15. Gilmore JP. Contribution of baroreceptors to the control of renal function. Circ Res 1964;14:301-317.
16. Schrier RW, Berl T. Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion. J Clin Invest 1973;52:502-511.
17. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236:F321-F332.
18. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol 1987;60:179-184.
19. Rouse D, Suki WN. Effects of neural and humoral agents on the renal tubules in congestive heart failure. Semin Nephrol 1994;14:412-426.
20. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984;55:669-675.
21. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
22. DiBona GF, Sawin LL. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol 1991;260:R298-R305.
23. DiBona GF, Sawin LL. Increased renal nerve activity in cardiac failure: arterial vs. cardiac baroreflex impairment. Am J Physiol 1995;268:R112-R116.
24. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197.
25. Higgins CB, Vatner SF, Millard RW, Franklin D, Braunwald E. Alterations in regional hemodynamics in experimental heart failure in conscious dogs. Trans Assoc Am Physicians 1972;85:267-278.
26. Millard RW, Higgins CB, Franklin D, Vatner SF. Regulation of the renal circulation during severe exercise in normal dogs and dogs with experimental heart failure. Circ Res 1972;31:881-888.
27. Middlekauff HR, Nitzsche EU, Hoh CK et al. Exaggerated renal vasoconstriction during exercise in heart failure patients. Circulation 2000;101:784-789.
28. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol 1988;254: R1017-R1024.
29. Viquerat CE, Daly P, Swedberg K et al. Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med 1985;78:455-460.
30. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
31. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989;256:F1015-F1020.
32. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153:937-942.
33. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987;31:1402-1415.
34. Suki WN. Renal hemodynamic consequences of angiotensinconverting enzyme inhibition in congestive heart failure. Arch Intern Med 1989;149:669-673.
35. Garvin JL. Angiotensin stimulates bicarbonate transport and Na+/K+ ATPase in rat proximal straight tubules. J Am Soc Nephrol 1991;1:1146-1152.
36. Wang T, Giebisch G. Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am J Physiol 1996;271:F143-F149.
37. Peti-Peterdi J, Warnock DG, Bell PD. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am Soc Nephrol 2002;13:1131-1135.
38. Garty H. Regulation of Na+ permeability by aldosterone. Semin Nephrol 1992;12:24-29.
39. Hensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 1991;11:441-446.
40. Goldsmith SR, Francis GS, Cowley AW, Jr., Goldenberg IF, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986;8:779-783.
41. Greenberg TT, Richmond WH, Stocking RA et al. Impaired atrial receptor responses in dogs with heart failure due to tricuspid insufficiency and pulmonary artery stenosis. Circ Res 1973;32:424-433.
42. Goldsmith SR, Francis GS, Cowley AW, Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986;58:295-299.
43. Funayama H, Nakamura T, Saito T et al. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 2004; 66:1387-1392.
44. Pedersen RS, Bentzen H, Bech JN, Nyvad O, Pedersen EB. Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney Int 2003; 63:1417-1425.
45. Wong NL, Tsui JK. Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collecting duct of cardiomyopathic hamsters is attenuated by enalapril treatment. Metabolism 2002;51:970-975.
46. Naitoh M, Suzuki H, Murakami M et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994; 267:H2245-H2254.
47. Schrier RW, Fassett RG, Ohara M, Martin PY. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy. Proc Assoc Am Physicians 1998;110:407-411.
48. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
49. Wei CM, Heublein DM, Perrella MA et al. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-1009.
50. Wei CM, Kao PC, Lin JT et al. Circulating beta-atrial natriuretic factor in congestive heart failure in humans. Circulation 1993;88:1016-1020.
51. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
52. Drexler H, Hirth C, Stasch HP et al. Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. Circ Res 1990;66:1371-1380.
53. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986; 324:473-476.
54. Stockand JD, Sansom SC. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease. Am J Kidney Dis 1997;29:971-981.
55. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987;326:697-698.
56. Dillingham MA, Anderson RJ. Inhibition of vasopressin action by atrial natriuretic factor. Science 1986;231:1572-1573.
57. Sonnenberg H, Honrath U, Chong CK, Wilson DR. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol 1986;250:F963-F966.
58. Oelkers W, Kleiner S, Bahr V. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans. Hypertension 1988;12:462-467.
59. Cody RJ, Atlas SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-1374.
60. Abraham WT, Hensen J, Kim JK et al. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol 1992;2:1697-1703.
61. Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steadystate infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
62. Yokota N, Bruneau BG, Kuroski T, de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994;94:1938-1946.
63. Badr KF, Ichikawa I. Prerenal failure: a deleterious shift from renal compensation to decompensation. N Engl J Med 1988;319:623-629.
64. Smith GL, Vaccarino V, Kosiborod M et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13-25.
65. Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003;41:2029-2035.
66. Butler J, Forman DE, Abraham WT et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-338.
67. Neuberg GW, Miller AB, O'Connor CM et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-38.
68. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
69. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC, Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 2003; 284:F1115-F1119.